Back to Search
Start Over
Serum estrogen receptor bioactivity and breast cancer risk among postmenopausal women.
- Source :
-
Endocrine-Related Cancer . Apr2014, Vol. 21 Issue 2, p263-273. 11p. - Publication Year :
- 2014
-
Abstract
- The estrogen levels of Asian women are different from those of Western women, and this could affect estrogen receptor (ER) bioactivity and breast cancer risk. We conducted a case-control study in 169 postmenopausal breast cancer cases and 426 matched controls nested within a population-based prospective cohort study, the Singapore Chinese Health Study, to evaluate the serum levels of estrogens and their receptor (ERa and ERb)-mediated estrogenic activities in relation to breast cancer risk. Breast cancer cases had higher levels of estrogens and ER-mediated bioactivities in baseline serum than the controls. Compared with those in the lowest quartile, women in the highest quartile for estrone (E1) or ERa-mediated bioactivity had increased breast cancer risk. After additional adjustment for ERb bioactivity, free estradiol, and E1 levels, serum ERa-mediated bioactivity remained associated with increased breast cancer risk. Compared with those in the lowest quartile, women in the highest quartile for ERa-mediated bioactivity had an odds ratio of 2.39 (95% CIZ1.17-4.88; P for trendZ0.016). Conversely, the positive association between E1 and cancer risk became null after adjustment for ERa-mediated bioactivity, suggesting that the effect of E1 could be mediated through ERÉ‘. Factor(s) contributing to increased ERa-mediated estrogenic bioactivity in serum and its role as a predictor for breast cancer risk need to be validated in future studies. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 13510088
- Volume :
- 21
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- Endocrine-Related Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 95911281
- Full Text :
- https://doi.org/10.1530/ERC-13-0233